JP6893917B2 - 神経変性疾患の処置 - Google Patents

神経変性疾患の処置 Download PDF

Info

Publication number
JP6893917B2
JP6893917B2 JP2018516056A JP2018516056A JP6893917B2 JP 6893917 B2 JP6893917 B2 JP 6893917B2 JP 2018516056 A JP2018516056 A JP 2018516056A JP 2018516056 A JP2018516056 A JP 2018516056A JP 6893917 B2 JP6893917 B2 JP 6893917B2
Authority
JP
Japan
Prior art keywords
signaling
inhibitor
egfr
myd88
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018516056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534259A5 (https=
JP2018534259A (ja
Inventor
ピーター リチャードソン，
ピーター リチャードソン，
リチャード ミード，
リチャード ミード，
ローラ フェライウォーロ，
ローラ フェライウォーロ，
ケネス パトリック マルバニー，
ケネス パトリック マルバニー，
Original Assignee
ベネボレントエーアイ バイオ リミテッド
ベネボレントエーアイ バイオ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベネボレントエーアイ バイオ リミテッド, ベネボレントエーアイ バイオ リミテッド filed Critical ベネボレントエーアイ バイオ リミテッド
Publication of JP2018534259A publication Critical patent/JP2018534259A/ja
Publication of JP2018534259A5 publication Critical patent/JP2018534259A5/ja
Application granted granted Critical
Publication of JP6893917B2 publication Critical patent/JP6893917B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018516056A 2015-09-24 2016-09-23 神経変性疾患の処置 Expired - Fee Related JP6893917B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1516905.5 2015-09-24
GBGB1516905.5A GB201516905D0 (en) 2015-09-24 2015-09-24 Treatment of Neurodegenerative diseases
PCT/GB2016/052970 WO2017051188A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2018534259A JP2018534259A (ja) 2018-11-22
JP2018534259A5 JP2018534259A5 (https=) 2019-10-31
JP6893917B2 true JP6893917B2 (ja) 2021-06-23

Family

ID=54544061

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516056A Expired - Fee Related JP6893917B2 (ja) 2015-09-24 2016-09-23 神経変性疾患の処置

Country Status (13)

Country Link
US (1) US20180263992A1 (https=)
EP (1) EP3352759A1 (https=)
JP (1) JP6893917B2 (https=)
KR (1) KR20180056695A (https=)
CN (1) CN108025005A (https=)
AU (1) AU2016329005A1 (https=)
BR (1) BR112018005855A2 (https=)
CA (1) CA2999390A1 (https=)
EA (1) EA201890647A1 (https=)
GB (1) GB201516905D0 (https=)
MA (1) MA42930A (https=)
MX (1) MX2018003619A (https=)
WO (1) WO2017051188A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077595A1 (en) 2014-11-12 2016-05-19 The General Hospital Corporation Methods for treating neurodegenerative diseases
GB201714307D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714316D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatement of neurodegenerative diseases
GB201714311D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714303D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN114099509B (zh) * 2020-08-26 2023-12-08 长庚大学 一种酪氨酸激酶抑制剂在制造用以治疗因炎性体激活所致相关疾病的药物中的用途
CN113694047A (zh) * 2021-08-31 2021-11-26 杭州师范大学 β-石竹烯在制备抗肿瘤药物中的应用
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US62342A (en) * 1867-02-26 Improved tool for the manufacture of paper bags
US257403A (en) * 1882-05-02 Electric lighting apparatus
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US20030232741A1 (en) * 2002-05-06 2003-12-18 Washington University Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
JP4328500B2 (ja) * 2002-07-25 2009-09-09 独立行政法人農業・食品産業技術総合研究機構 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2004092154A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CA2555457C (en) * 2004-02-09 2012-08-21 Mitsubishi Pharma Corporation A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
ES2364495T3 (es) * 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
US7449442B2 (en) * 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
JP2008061505A (ja) * 2006-09-04 2008-03-21 Hisamitsu Pharmaceut Co Inc 筋萎縮性側索硬化症の治療剤のスクリーニング方法
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
CA2778483A1 (en) * 2009-10-22 2011-04-28 Genentech, Inc. Modulation of axon degeneration
BR112015001838B1 (pt) * 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo

Also Published As

Publication number Publication date
MA42930A (fr) 2018-08-01
BR112018005855A2 (pt) 2018-10-16
KR20180056695A (ko) 2018-05-29
EP3352759A1 (en) 2018-08-01
CA2999390A1 (en) 2017-03-30
WO2017051188A1 (en) 2017-03-30
CN108025005A (zh) 2018-05-11
GB201516905D0 (en) 2015-11-11
JP2018534259A (ja) 2018-11-22
US20180263992A1 (en) 2018-09-20
EA201890647A1 (ru) 2018-09-28
AU2016329005A1 (en) 2018-04-19
MX2018003619A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
JP6893917B2 (ja) 神経変性疾患の処置
US20100056604A1 (en) Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv
US20060216339A1 (en) Neuronal pain pathway
KR20210132219A (ko) 암의 치료를 위한 조합 요법
CN110652514A (zh) 第三代egfr抑制剂的制药用途
US20200384001A1 (en) Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase
KR20140072028A (ko) Pi3k- 및 mek-억제제의 상승작용적 조합물
WO2018053373A1 (en) Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
US20200215074A1 (en) Method of Treatment of Cancer
CA3196283A1 (en) Csf1r kinase inhibitor and use thereof
US20220218715A1 (en) Novel use of pyrrolo-pyridine derivative compound for prevention and/or treatment of cancer
US20220313702A1 (en) Oxathiazin compounds for inhibiting gapdh
US6727260B2 (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
JP2004520404A (ja) ＧＳＫ−３β活性の調整およびその種々の使用
US20210069189A1 (en) Treatment of neurodegenerative diseases
TW202021968A (zh) 用於治療眼部疾病之方法及藥物組合物
JP7806124B2 (ja) 自閉症スペクトラム障害を治療または予防するためのバリポデクト（Ｂａｌｉｐｏｄｅｃｔ）
US20230165873A1 (en) Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19
WO2019048853A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
WO2019048851A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
CN120346202A (zh) Ripk1抑制剂及其在治疗神经功能障碍中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210506

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210602

R150 Certificate of patent or registration of utility model

Ref document number: 6893917

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees